MannKind Corporation MNKD
MannKind Corporation (Nasdaq: MNKD) is a cardio-renal-metabolic drug developer. Its lead program, Afrezza (insulin human) Inhalation Powder, is in Phase 2 for Diabetes mellitus (adults; label expanded to ages 6 and older May 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Afrezza | Diabetes (adult and pediatric ages 6+) | protein/peptide | Approved |
| Furoscix (furosemide injection, incl. ReadyFlow autoinjector) | Edema in heart failure / chronic kidney disease | device-combination | Approved |
| MNKD-201 (inhaled nintedanib dry powder) | Idiopathic pulmonary fibrosis | small molecule | Phase 2 |
| MNKD-701 (inhaled bumetanide) | Fluid overload (feasibility) | small molecule | Pre-clinical |
Recent results and decisions
- Aug 5, 2026positive Topline Phase 1b INFLO-1 data showed nintedanib DPI was safe and well tolerated in IPF patients, supporting Phase 2 advancement; no efficacy numbers given.
Topline data readout of U.S. Phase 1b INFLO-1 demonstrates safety and tolerability in IPF patients
Filing - Jul 23, 2026approval FDA approved FUROSCIX ReadyFlow on July 23, 2026, an autoinjector delivering IV-equivalent diuretic therapy; commercial availability expected late August.
Received FDA approval of Furoscix ReadyFlow™ on July 23, 2026, the first and only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema in adults with heart failure (HF) or chronic kidney disease (CKD)
Filing - May 29, 2026approval FDA approved Afrezza on May 29, 2026 for children and adolescents ages 6 and older with diabetes (pediatric sBLA).
Received FDA approval of Afrezza on May 29, 2026 for use in children and adolescents ages 6 and older living with diabetes
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.